← Eichor
Study identifier: NCT06737926 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effects of Sensorimotor Training With Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients

Condition: Chemotherapy Induced Peripheral Neuropathy · Breast Cancer Patients  ·  Sponsor: Riphah International University

PhaseNA
Planned participants24
Who can joinFemale, 30 Years to 65 Years
Healthy volunteersNo

About this study

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a prevalent and clinically relevant side effect of chemotherapy in breast cancer patients. It occurs in 30-70% of cases. It can cause various sensory and motor symptoms. Specific exercise interventions have proven promising to target relevant symptoms. Therefore, the objective of this study is to determine the effects of Sensorimotor training on pain intensity, perceived balance confidence, and functional exercise capacity with chemotherapy-induced peripheral neuropathy in breast cancer patients.

This description comes directly from the study's public registry record.

Talk to the study team

Imran Amjad, PHD  ·  03324390125  ·  imran.amjad@riphah.edu.pk

Always discuss trial participation with your own doctor first.

Locations (2)

Mayo Hospital LahoreLahore, Punjab Province, PakistanRecruiting
Mayo HospitalLahore, Punjab Province, PakistanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06737926